Hemptown USA, a grower of full-spectrum hemp biomass, anticipates a growing capacity expansion in 2019. According to Wolterman, company's founder and chairman, Hemptown farmed 110 acres in 2018. The enterprise anticipates scaling up in 2019 to reach a capacity of 1,000 to 1,500 acres. This capacity is expected to enable Hemptown to produce in excess of one million pounds of biomass.
Hemptown focuses its efforts on multiple cannabinoids, going beyond CBD. The company has a proprietary genetics program with strains that are high in various alternative cannabinoids like CBG and CBN. Currently, Hemptown holds an agreement for one million rare CBG seeds to be grown in 2019 and the coming years.
"CBG is currently considered a minor cannabinoid, because it’s not present in large quantities in traditional plants. Cannabinoid manufacturers are carrying out genetic programs to modify strains and maximize yields. In terms of health benefits, CBG produces results that are comparable to those of CBD. It has a positive impact on the functioning of the endocannabinoid system – a mechanism that works to keep the body in a balanced state of homeostasis. Research suggests that CBG is an effective option for the treatment of glaucoma or inflammatory bowel disease, is a powerful antibacterial agent and may even have some cancer fighting properties. Scientific work is ongoing to identify the full scope of CBG effects, as well as the health benefits resulting from a combination of CBG and other cannabinoids," the team with the company explains.